Ozempic and Meningioma Risk
There is no evidence linking Ozempic (semaglutide) to meningioma development, and you can safely continue it even with a history of meningioma. The FDA label does not list meningioma as a contraindication or warning, and available research shows no association between GLP-1 receptor agonists and meningioma risk 1.
Key Evidence
FDA-Approved Safety Profile
The official Ozempic prescribing information lists only two contraindications 1:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide
Meningioma is notably absent from all contraindications, warnings, and precautions in the FDA label 1.
Cancer Safety Data
A comprehensive 2023 systematic review and meta-analysis of 37 randomized controlled trials (16,839 placebo-controlled patients and 16,550 active-controlled patients) plus 19 real-world studies found 2:
- No increased risk of any cancer types with semaglutide
- Specifically for all neoplasms (benign, malignant, and unspecified): OR 0.95 (95% CI: 0.62-1.45) versus placebo
- High grade of evidence supporting cancer safety
A 2021 comprehensive safety review confirmed no unexpected safety issues with semaglutide, with a favorable overall risk/benefit profile 3.
Meningioma-Specific Context
What Actually Increases Meningioma Risk
The confusion may stem from hormone-related meningioma risks. Certain progestogens are associated with meningioma:
- Nomegestrol acetate shows strong dose-dependent association (RR 12.0 for cumulative doses >6g) 4
- Hormone replacement therapy may increase meningioma risk 5
Semaglutide is a GLP-1 receptor agonist—not a hormone—and works through completely different mechanisms involving glucose regulation and appetite control 6.
Clinical Recommendation
Continue Ozempic without concern for meningioma risk. The medication provides significant benefits for:
- Glycemic control in type 2 diabetes
- Cardiovascular risk reduction (reducing MACE events) 7, 6
- Weight management 6
- Heart failure with preserved ejection fraction symptoms 7
Monitoring Considerations
If you have a known meningioma, standard neurosurgical surveillance should continue based on tumor characteristics, not medication use. The only cancer-related monitoring specific to Ozempic involves thyroid nodules or elevated calcitonin (for medullary thyroid carcinoma risk from animal studies) 1.
The evidence is clear: semaglutide and meningioma are unrelated, and there is no reason to discontinue this medication based on meningioma history.